Fennec Pharmaceuticals (FENC) News Today → Tiny AI projects with huge promise hiding in plain sight … (From Weiss Ratings) (Ad) Free FENC Stock Alerts $7.12 +0.14 (+2.01%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 9:57 AM | marketbeat.comHC Wainwright Research Analysts Raise Earnings Estimates for Fennec Pharmaceuticals Inc (NASDAQ:FENC)Fennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) - Equities researchers at HC Wainwright increased their FY2025 earnings estimates for Fennec Pharmaceuticals in a research note issued to investors on Wednesday, May 15th. HC Wainwright analyst R. Selvaraju now expects that the company will eMay 16 at 3:49 AM | markets.businessinsider.comMaintained Buy Rating for Fennec Pharmaceuticals Amidst Revenue Growth and Strategic PartnershipsMay 16 at 3:49 AM | markets.businessinsider.comFennec Pharmaceuticals: Temporary Setbacks with Strong Long-Term OutlookMay 15 at 3:02 PM | marketbeat.comFennec Pharmaceuticals (NASDAQ:FENC) Given New $17.00 Price Target at Craig HallumCraig Hallum decreased their price objective on shares of Fennec Pharmaceuticals from $20.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday.May 15 at 2:53 PM | marketbeat.comFennec Pharmaceuticals (NASDAQ:FENC) Releases Quarterly Earnings Results, Misses Expectations By $0.08 EPSFennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported $0.41 earnings per share for the quarter, missing analysts' consensus estimates of $0.49 by ($0.08). The business had revenue of $25.38 million for the quarter, compared to the consensus estimate of $10.46 million. During the same period last year, the firm earned ($0.23) earnings per share.May 15 at 5:36 AM | americanbankingnews.comFennec Pharmaceuticals (NASDAQ:FENC) Rating Reiterated by WedbushMay 14 at 4:15 PM | marketbeat.comFennec Pharmaceuticals (NASDAQ:FENC) Receives Outperform Rating from WedbushWedbush reiterated an "outperform" rating and set a $16.00 target price on shares of Fennec Pharmaceuticals in a research note on Tuesday.May 14 at 12:20 PM | investorplace.comFENC Stock Earnings: Fennec Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024May 14 at 9:43 AM | finance.yahoo.comFennec Pharmaceuticals Inc.'s (NASDAQ:FENC) largest shareholders are individual investors who were rewarded as market cap surged US$25m last weekMay 14 at 6:03 AM | globenewswire.comFennec Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 12, 2024 | americanbankingnews.comFennec Pharmaceuticals (FENC) to Release Earnings on TuesdayMay 8, 2024 | marketbeat.comFennec Pharmaceuticals (FENC) Scheduled to Post Quarterly Earnings on TuesdayFennec Pharmaceuticals (NASDAQ:FENC) will be releasing earnings before the market opens on Tuesday, May 14, Zacks reports.May 7, 2024 | globenewswire.comFennec Pharmaceuticals to Report First Quarter 2024 Financial Results on May 14, 2024May 6, 2024 | americanbankingnews.comFennec Pharmaceuticals Inc Forecasted to Post Q4 2024 Earnings of $0.06 Per Share (NASDAQ:FENC)May 3, 2024 | insidertrades.comFennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Sells $22,146.41 in StockApril 23, 2024 | insidertrades.comAdrian Haigh Sells 22,223 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) StockApril 23, 2024 | insidertrades.comFennec Pharmaceuticals Inc (NASDAQ:FENC) COO Adrian Haigh Sells 22,222 SharesApril 22, 2024 | marketbeat.comFennec Pharmaceuticals Inc (NASDAQ:FENC) COO Sells $207,118.36 in StockFennec Pharmaceuticals Inc (NASDAQ:FENC - Get Free Report) COO Adrian Haigh sold 22,223 shares of the firm's stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $9.32, for a total value of $207,118.36. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.April 20, 2024 | investing.comFennec Pharmaceuticals COO sells shares worth over $536kApril 19, 2024 | insidertrades.comFennec Pharmaceuticals Inc (NASDAQ:FENC) COO Sells $220,220.02 in StockApril 18, 2024 | insidertrades.comFennec Pharmaceuticals Inc (NASDAQ:FENC) COO Sells $228,886.60 in StockApril 9, 2024 | finance.yahoo.comThose who invested in Fennec Pharmaceuticals (NASDAQ:FENC) five years ago are up 136%April 7, 2024 | uk.investing.comFennec Pharmaceuticals CEO sells shares worth over $950kApril 6, 2024 | insidertrades.comInsider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Sells 44,300 Shares of StockApril 5, 2024 | marketbeat.comFennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Rosty Raykov Sells 44,300 SharesFennec Pharmaceuticals Inc (NASDAQ:FENC - Get Free Report) CEO Rosty Raykov sold 44,300 shares of Fennec Pharmaceuticals stock in a transaction on Friday, April 5th. The stock was sold at an average price of $10.75, for a total transaction of $476,225.00. Following the sale, the chief executive officer now directly owns 187,471 shares in the company, valued at approximately $2,015,313.25. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.April 5, 2024 | marketbeat.comHC Wainwright Comments on Fennec Pharmaceuticals Inc's Q2 2024 Earnings (NASDAQ:FENC)Fennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) - Equities research analysts at HC Wainwright dropped their Q2 2024 EPS estimates for shares of Fennec Pharmaceuticals in a note issued to investors on Thursday, April 4th. HC Wainwright analyst R. Selvaraju now forecasts that the company wilApril 5, 2024 | insidertrades.comRosty Raykov Sells 40,584 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) StockApril 4, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Fennec Pharmaceuticals Following Strategic European Licensing Deal and Strong Financial OutlookApril 4, 2024 | marketbeat.comFennec Pharmaceuticals (NASDAQ:FENC) PT Raised to $18.00 at HC WainwrightHC Wainwright upped their target price on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the company a "buy" rating in a report on Thursday.April 3, 2024 | marketbeat.comInsider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) CEO Sells 40,584 Shares of StockFennec Pharmaceuticals Inc (NASDAQ:FENC - Get Free Report) CEO Rosty Raykov sold 40,584 shares of the stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $10.78, for a total transaction of $437,495.52. Following the transaction, the chief executive officer now directly owns 276,054 shares of the company's stock, valued at approximately $2,975,862.12. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.March 28, 2024 | insidertrades.comFennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells $23,190.58 in StockMarch 27, 2024 | finance.yahoo.comChief Financial Officer Robert Andrade Sells 13,975 Shares of Fennec Pharmaceuticals Inc (FENC)March 26, 2024 | insidertrades.comFennec Pharmaceuticals Inc (NASDAQ:FENC) CFO Sells $153,725.00 in StockMarch 26, 2024 | finance.yahoo.comChief Financial Officer Robert Andrade Sells Shares of Fennec Pharmaceuticals Inc (FENC)March 25, 2024 | marketbeat.comInsider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) CFO Sells 13,975 Shares of StockFennec Pharmaceuticals Inc (NASDAQ:FENC - Get Free Report) CFO Robert Andrade sold 13,975 shares of Fennec Pharmaceuticals stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $11.00, for a total value of $153,725.00. Following the completion of the transaction, the chief financial officer now owns 105,746 shares of the company's stock, valued at $1,163,206. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.March 22, 2024 | markets.businessinsider.comBuy Rating for Fennec Pharmaceuticals Amidst Strong Pedmark Sales and Market Expansion PotentialMarch 22, 2024 | finance.yahoo.comQ4 2023 Fennec Pharmaceuticals Inc Earnings CallMarch 22, 2024 | marketbeat.comEquities Analysts Set Expectations for Fennec Pharmaceuticals Inc's Q3 2024 Earnings (NASDAQ:FENC)Fennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) - Wedbush reduced their Q3 2024 EPS estimates for shares of Fennec Pharmaceuticals in a research report issued to clients and investors on Thursday, March 21st. Wedbush analyst D. Nierengarten now anticipates that the company will post earninMarch 21, 2024 | investorplace.comFENC Stock Earnings: Fennec Pharmaceuticals Misses EPS, Beats Revenue for Q4 2023March 21, 2024 | globenewswire.comFennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business UpdateMarch 20, 2024 | marketbeat.comFennec Pharmaceuticals (FENC) Set to Announce Quarterly Earnings on ThursdayFennec Pharmaceuticals (NASDAQ:FENC) will be releasing earnings before the market opens on Thursday, March 21, Zacks reports.March 20, 2024 | marketbeat.comWedbush Comments on Fennec Pharmaceuticals Inc's FY2024 Earnings (NASDAQ:FENC)Fennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) - Stock analysts at Wedbush dropped their FY2024 earnings estimates for Fennec Pharmaceuticals in a note issued to investors on Monday, March 18th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of $0.37 per sMarch 19, 2024 | bizjournals.comRTP firm inks licensing deal for European drug launchMarch 19, 2024 | marketbeat.comWedbush Comments on Fennec Pharmaceuticals Inc's Q2 2024 Earnings (NASDAQ:FENC)Fennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) - Analysts at Wedbush lowered their Q2 2024 earnings per share (EPS) estimates for shares of Fennec Pharmaceuticals in a note issued to investors on Monday, March 18th. Wedbush analyst D. Nierengarten now expects that the company will post eaMarch 19, 2024 | globenewswire.comFennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 2024March 18, 2024 | marketbeat.comFennec Pharmaceuticals (NASDAQ:FENC) PT Raised to $18.00 at Craig HallumCraig Hallum upped their price target on shares of Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a "buy" rating in a research report on Monday.March 18, 2024 | marketbeat.comFennec Pharmaceuticals' (FENC) "Outperform" Rating Reaffirmed at WedbushWedbush reiterated an "outperform" rating and issued a $16.00 price objective on shares of Fennec Pharmaceuticals in a research note on Monday.March 17, 2024 | globenewswire.comFennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New ZealandMarch 16, 2024 | finance.yahoo.comFENC Apr 2024 12.500 callMarch 14, 2024 | msn.comNearly 1,000 Family Dollar stores are closing, owner Dollar Tree announces Get Fennec Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter. Email Address Tiny AI projects with huge promise hiding in plain sight … (Ad)I’ve developed a system that’s helped me find huge winners in the past. Now my system has alerted me to the next four altcoins that could be the next superstars. Click here to find out who they are. FENC Media Mentions By Week FENC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FENC News Sentiment▼0.040.55▲Average Medical News Sentiment FENC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FENC Articles This Week▼191▲FENC Articles Average Week Get Fennec Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Kodiak Sciences News Century Therapeutics News Elevation Oncology News INmune Bio News Opthea News Innate Pharma News Adverum Biotechnologies News Genfit News Compugen News Acumen Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FENC) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon’s New Device is About to Shock the WorldInvestorPlaceUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
